What markers track lean mass preservation?
A research-supply overview of candidate markers and trial endpoints used to assess lean mass preservation during obesity pharmacotherapy, including multi-receptor agonists and antibody-based combinations.
Lean mass preservation refers to the retention of fat-free mass — skeletal muscle, bone, and organ tissue — during periods of pharmacologically induced weight loss. In the research literature, this is assessed through a set of candidate markers and imaging endpoints rather than a single analyte. The class of interventions under study includes GLP-1 receptor agonists (GLP-1RAs), multi-receptor agonists, and antibody-based combinations such as trevogrumab (an anti-myostatin antibody) and garetosmab (an anti-activin A antibody) [2]. No single sequence, formula, or molecular weight is given in the evidence for these markers as a group; they are defined operationally by the trial protocols that measure them.
The work centres on the GLP-1 receptor and related incretin and metabolic receptor families, with antibody arms targeting the myostatin/activin signalling axis [1][2].
Research Studies
Trevogrumab and garetosmab with semaglutide in adults with obesity
A three-part study is testing trevogrumab alone and trevogrumab with garetosmab, each combined with semaglutide, in adult participants. Part A enrols healthy participants to assess safety and tolerability; Parts B and C enrol participants with obesity to assess safety and effectiveness when combined with semaglutide. The stated aims include weight loss, fat loss, and lean mass preservation [2].
Semaglutide and lean mass endpoints in obesity pharmacotherapy
GLP-1RAs have transformed obesity treatment, achieving weight loss previously considered attainable only with bariatric surgery. However, GLP-1-based therapies have revealed important limitations, including weight loss plateaus, substantial inter-individual variability, and weight regain upon discontinuation [1]. These limitations motivate the study of markers that distinguish fat loss from lean mass loss.
Multi-receptor agonists and body composition outcomes
Existing reviews have focused predominantly on approved GLP-1RAs, with limited synthesis of emerging multi-receptor agonists, oral formulations, and body composition outcomes [1]. This gap is relevant to lean mass preservation because multi-receptor agonists may produce different body composition profiles than single-receptor agonists.
Inter-individual variability as a marker context
Substantial inter-individual variability in response to GLP-1-based therapies is documented [1]. In research settings, this variability is a reason to report lean mass markers alongside total weight change rather than as a single composite.
Weight regain upon discontinuation and lean mass tracking
Weight regain upon discontinuation of GLP-1-based therapies is described in the literature [1]. Whether regain includes disproportionate lean mass recovery is not specified in the evidence provided.
Animal-only and in vitro evidence
The evidence block does not supply animal-only or in vitro studies on lean mass preservation markers. Claims in this article are therefore limited to the clinical and review sources cited.
Comparison of trial arms and endpoints
The table below summarises the trial structure and stated aims from the ClinicalTrials.gov record [2].
| Part | Population | Study drugs | Stated aims |
|---|---|---|---|
| Part A | Healthy participants | Trevogrumab, garetosmab | Safety and tolerability |
| Part B | Participants with obesity | Trevogrumab with semaglutide | Safety and effectiveness with semaglutide |
| Part C | Participants with obesity | Trevogrumab with garetosmab and semaglutide | Safety and effectiveness with semaglutide |
Markers named in the evidence
The evidence names weight loss, fat loss, and lean mass preservation as outcomes of interest [2]. It does not provide numerical thresholds, assay specifications, or reference ranges for these markers.
Limitations of current marker synthesis
Reviews have focused predominantly on approved GLP-1RAs, with limited synthesis of emerging multi-receptor agonists, oral formulations, and body composition outcomes [1]. This limits the ability to compare lean mass preservation markers across drug classes.
If you are reading this for personal health reasons
The materials described here are sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies
- [2] A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation